{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-054950","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.323737+00:00","generated_at":"2026-06-02T12:29:36.809740+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Janux Therapeutics Q1 2024: Cash $651.8M; net loss $14.8M; trials ongoing","bullets":["Cash and short-term investments $651.8M as of March 31, 2024, up from $344.0M at Dec 31, 2023.","Net loss $14.8M for Q1 2024, improved from $17.5M in Q1 2023; R&D expenses $14.1M vs $15.9M.","Enrollment ongoing in Phase 1 trials for JANX007 (PSMA-TRACTr in mCRPC) and JANX008 (EGFR-TRACTr in solid tumors).","JANX007 data update and expansion cohort doses anticipated in 2H 2024; JANX008 data expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-054950","json":"https://secwatch.observer/filing/0000950170-24-054950.json","markdown":"https://secwatch.observer/filing/0000950170-24-054950.md","text":"https://secwatch.observer/filing/0000950170-24-054950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024054950/0000950170-24-054950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024054950/janx-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:29:36.809740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b48cb827b6cc8002c37b2706be5009c292967a55","claim":"Janux Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss of $14.8 million.","evidence_excerpt":"Janux Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024054950/0000950170-24-054950-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss of $14.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}